Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for KYMR

Stock NameKymera Therapeutics Inc
TickerKYMR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS5015751044

Show aggregate KYMR holdings

News associated with KYMR

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Barclays
Barclays initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a report published on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $60.00 price target on the stock. Other research analysts have also issued research reports about the stock. BTIG Research reiterated a “buy” rating and set a $59.00 […] - 2025-09-18 05:13:29
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $58.76
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received an average rating of “Buy” from the nineteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The […] - 2025-09-08 02:50:52
Wednesday's ETF with Unusual Volume: FYC
The First Trust Small Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 111,000 shares traded versus three month average volume of about 27,000. Shares of FYC were up about 0.4% on the day. Components of that ETF with the hi - 2025-08-27 13:50:50
Kymera Therapeutics (NASDAQ:KYMR) Rating Lowered to Sell at Wall Street Zen
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday. Other analysts have also recently issued reports about the stock. Oppenheimer restated an “outperform” rating and set a $53.00 target price (down from $56.00) on […] - 2025-08-18 04:46:57
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $59.11 Consensus PT from Analysts
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average recommendation of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. […] - 2025-08-14 02:32:51
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $40.62, but opened at $38.16. Kymera Therapeutics shares last traded at $39.34, with a volume of 134,694 shares trading hands. The company reported […] - 2025-08-13 02:17:07
Notable Two Hundred Day Moving Average Cross - KYMR
In trading on Monday, shares of Kymera Therapeutics Inc (Symbol: KYMR) crossed below their 200 day moving average of $39.13, changing hands as low as $36.65 per share. Kymera Therapeutics Inc shares are currently trading off about 2.8% on the day. The chart below shows the one - 2025-08-11 12:49:18
Kymera Revenue Drops 55 Percent in Q2
Key PointsGAAP revenue declined sharply from $25.7 million in Q2 2024 to $11.5 million in Q2 2025, missing analyst expectations by 48.4% for Q2 2025 (GAAP). - 2025-08-11 08:28:41
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Analysts at Morgan Stanley
Morgan Stanley assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report released on Thursday morning. The brokerage issued an overweight rating and a $70.00 price objective on the stock. A number of other research analysts also recently issued reports on the company. Guggenheim reissued a “buy” rating and issued […] - 2025-07-04 04:59:46
Bvf Partners L. P/Il Buys 317,167 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bvf Partners L. P/Il purchased 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director […] - 2025-07-03 05:26:56
Wells Fargo & Company Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00
Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $53.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts have also issued research reports about the company. Wall Street Zen upgraded Kymera Therapeutics from […] - 2025-06-27 04:46:43
We Did The Math TMSL Can Go To $38
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:53:34
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to “Buy” Rating
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $51.00 price target on the stock. Bank of America‘s price objective points to a potential […] - 2025-06-04 02:50:56
Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) shares saw strong trading volume on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $57.00 to $64.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. 961,245 shares changed hands during mid-day trading, an increase of 62% from […] - 2025-06-04 02:01:25
Universal Beteiligungs und Servicegesellschaft mbH Invests $4.61 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 114,587 shares of the company’s stock, valued at approximately $4,610,000. Universal Beteiligungs und […] - 2025-06-02 05:36:54
Bank of America Corp DE Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Bank of America Corp DE cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 43.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,260 shares of the company’s stock after selling 48,772 shares during the quarter. Bank of America […] - 2025-06-02 04:38:48
BNP Paribas Financial Markets Makes New $396,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
BNP Paribas Financial Markets acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,838 shares of the company’s stock, valued at approximately $396,000. Several other hedge […] - 2025-05-26 04:24:47
D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
D. E. Shaw & Co. Inc. cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 56.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 82,578 shares of the company’s stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Kymera Therapeutics were worth […] - 2025-05-19 05:12:56
Northern Trust Corp Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Northern Trust Corp raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 14.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,833 shares of the company’s stock after acquiring an additional 53,658 shares during the quarter. Northern Trust Corp’s holdings in Kymera Therapeutics were worth $17,614,000 as of […] - 2025-05-15 05:38:47
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Comerica Bank
Comerica Bank cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 45.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 20,631 shares of the company’s stock after selling 17,442 shares during the quarter. Comerica Bank’s holdings in Kymera Therapeutics were worth $830,000 at the end of the most recent reporting […] - 2025-05-14 05:19:05
Guggenheim Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR)
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They presently have a $52.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 66.99% from the company’s current price. A number of […] - 2025-05-14 03:10:53
Tower Research Capital LLC TRC Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 95.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,812 shares of the company’s stock after purchasing an additional 2,350 shares during the […] - 2025-05-06 05:16:52
Marshall Wace LLP Sells 110,846 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Marshall Wace LLP decreased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 94.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,835 shares of the company’s stock after selling 110,846 shares during the period. Marshall Wace LLP’s holdings in […] - 2025-05-05 05:04:51
Wells Fargo & Company MN Has $883,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Wells Fargo & Company MN grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 51.8% during the fourth quarter, Holdings Channel reports. The firm owned 21,939 shares of the company’s stock after acquiring an additional 7,487 shares during the quarter. Wells Fargo & Company MN’s holdings in Kymera Therapeutics were worth $883,000 […] - 2025-05-01 04:35:02
Franklin Resources Inc. Acquires 8,927 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Franklin Resources Inc. raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 30.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,367 shares of the company’s stock after acquiring an additional 8,927 shares during the period. Franklin Resources Inc. owned approximately 0.06% […] - 2025-04-15 05:32:48
Alliancebernstein L.P. Cuts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Alliancebernstein L.P. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 29.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,246 shares of the company’s stock after selling 36,368 shares during the quarter. Alliancebernstein L.P.’s holdings in Kymera Therapeutics were worth $3,550,000 as of its most recent filing with the […] - 2025-04-15 04:50:48
Norges Bank Invests $3.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Norges Bank acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 91,231 shares of the company’s stock, valued at approximately $3,670,000. Several other large investors have also bought and […] - 2025-04-11 05:12:59
Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $56.36
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-04-11 03:08:47
Vanguard Group Inc. Acquires 133,546 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 2.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,887,312 shares of the company’s stock after purchasing an additional 133,546 shares during the quarter. Vanguard Group Inc. owned about 0.08% of Kymera Therapeutics worth $196,617,000 […] - 2025-04-07 04:34:48
Teacher Retirement System of Texas Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Teacher Retirement System of Texas raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 35.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,490 shares of the company’s stock after purchasing an additional 3,026 shares during the period. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth […] - 2025-04-01 04:40:45

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) KYMR holdings

DateNumber of KYMR Shares HeldBase Market Value of KYMR SharesLocal Market Value of KYMR SharesChange in KYMR Shares HeldChange in KYMR Base ValueCurrent Price per KYMR Share HeldPrevious Price per KYMR Share Held
2025-11-11 (Tuesday)46,486USD 2,945,818USD 2,945,818
2025-11-10 (Monday)46,486KYMR holding increased by 119USD 2,847,732KYMR holding increased by 127844USD 2,847,732119USD 127,844 USD 61.26 USD 58.66
2025-11-07 (Friday)46,367USD 2,719,888KYMR holding decreased by -108499USD 2,719,8880USD -108,499 USD 58.66 USD 61
2025-11-06 (Thursday)46,367KYMR holding increased by 119USD 2,828,387KYMR holding increased by 58594USD 2,828,387119USD 58,594 USD 61 USD 59.89
2025-11-05 (Wednesday)46,248USD 2,769,793KYMR holding decreased by -925USD 2,769,7930USD -925 USD 59.89 USD 59.91
2025-11-04 (Tuesday)46,248KYMR holding increased by 119USD 2,770,718KYMR holding increased by 15894USD 2,770,718119USD 15,894 USD 59.91 USD 59.72
2025-11-03 (Monday)46,129USD 2,754,824KYMR holding decreased by -97793USD 2,754,8240USD -97,793 USD 59.72 USD 61.84
2025-10-31 (Friday)46,129USD 2,852,617KYMR holding increased by 18451USD 2,852,6170USD 18,451 USD 61.84 USD 61.44
2025-10-30 (Thursday)46,129KYMR holding increased by 595USD 2,834,166KYMR holding increased by 100760USD 2,834,166595USD 100,760 USD 61.44 USD 60.03
2025-10-29 (Wednesday)45,534KYMR holding increased by 238USD 2,733,406KYMR holding decreased by -72681USD 2,733,406238USD -72,681 USD 60.03 USD 61.95
2025-10-28 (Tuesday)45,296USD 2,806,087KYMR holding increased by 49825USD 2,806,0870USD 49,825 USD 61.95 USD 60.85
2025-10-27 (Monday)45,296USD 2,756,262KYMR holding increased by 103728USD 2,756,2620USD 103,728 USD 60.85 USD 58.56
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of KYMR by Blackrock for IE00BYXG2H39

Show aggregate share trades of KYMR

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY11962.10058.865 59.189USD 7,043 41.23
2025-11-06BUY11961.24559.200 59.405USD 7,069 41.04
2025-11-04BUY11961.58055.660 56.252USD 6,694 40.85
2025-10-30BUY59561.78659.240 59.495USD 35,399 40.53
2025-10-29BUY23860.03061.810 61.632USD 14,668 40.43
2025-10-22SELL-47655.80059.190 58.851USD -28,013 39.92 Loss of -9,009 on sale
2025-10-20BUY23860.50061.825 61.693USD 14,683 39.71
2025-10-17BUY59559.83061.610 61.432USD 36,552 39.60
2025-10-15BUY95262.89063.290 63.250USD 60,214 39.47
2025-10-03BUY82657.90059.000 58.890USD 48,643 39.26
2025-10-02BUY11856.00056.145 56.131USD 6,623 39.17
2025-09-30BUY23656.60058.930 58.697USD 13,852 38.98
2025-09-26BUY23656.25056.810 56.754USD 13,394 38.77
2025-09-25BUY23653.73553.840 53.830USD 12,704 38.69
2025-09-24BUY1,51252.50052.575 52.568USD 79,482 38.60
2025-09-18BUY11351.16051.800 51.736USD 5,846 38.53
2025-09-17BUY33948.12050.690 50.433USD 17,097 38.48
2025-08-20SELL-45242.35042.930 42.872USD -19,378 38.35 Loss of -2,045 on sale
2025-07-30BUY45244.07044.940 44.853USD 20,274 38.21
2025-07-17SELL-22646.35046.925 46.867USD -10,592 37.77 Loss of -2,055 on sale
2025-07-16BUY61845.51046.000 45.951USD 28,398 37.72
2025-07-11SELL-88844.48045.150 45.083USD -40,034 37.58 Loss of -6,664 on sale
2025-07-07BUY33343.81044.460 44.395USD 14,784 37.39
2025-07-02BUY6,10544.53045.460 45.367USD 276,966 37.28
2025-06-20BUY71045.87046.660 46.581USD 33,073 37.22
2025-06-11BUY21848.39050.270 50.082USD 10,918 36.71
2025-06-10BUY21848.60049.020 48.978USD 10,677 36.62
2025-06-04SELL-10944.26045.450 45.331USD -4,941 36.31 Loss of -984 on sale
2025-04-23BUY10930.70031.070 31.033USD 3,383 37.64
2025-04-10SELL-87222.40023.430 23.327USD -20,341 38.86 Profit of 13,541 on sale
2025-04-08SELL-10921.05023.778 23.505USD -2,562 39.23 Profit of 1,714 on sale
2025-04-07SELL-10922.01022.480 22.433USD -2,445 39.43 Profit of 1,853 on sale
2025-04-04SELL-55022.07022.990 22.898USD -12,594 39.64 Profit of 9,206 on sale
2025-04-01BUY1,27925.23527.365 27.152USD 34,727 39.97
2025-03-31SELL-32127.37028.750 28.612USD -9,184 40.12 Profit of 3,695 on sale
2025-03-21BUY1,47832.54033.900 33.764USD 49,903 40.81
2025-03-14SELL-1,63234.37034.990 34.928USD -57,002 41.29 Profit of 10,389 on sale
2025-03-07SELL-20432.89033.560 33.493USD -6,833 41.88 Profit of 1,711 on sale
2025-03-04SELL-10230.68030.960 30.932USD -3,155 42.37 Profit of 1,166 on sale
2025-02-25BUY20434.71035.725 35.623USD 7,267 43.23
2025-02-19SELL-10237.65038.240 38.181USD -3,894 43.71 Profit of 564 on sale
2025-02-13BUY30636.63036.750 36.738USD 11,242 44.25
2025-02-12BUY10235.15035.510 35.474USD 3,618 44.44
2025-02-11BUY40834.41036.150 35.976USD 14,678 44.65
2024-12-30SELL-3,49139.32039.840 39.788USD -138,900 46.81 Profit of 24,523 on sale
2024-11-18SELL-1,66542.41043.080 43.013USD -71,617 48.33 Profit of 8,859 on sale
2024-11-08SELL-11150.95051.130 51.112USD -5,673 48.03 Loss of -342 on sale
2024-10-21SELL-11146.56046.885 46.852USD -5,201 0.00 Loss of -5,201 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of KYMR

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19309,0463,591440,76070.1%
2025-09-18223,3017,626444,00250.3%
2025-09-17307,0711,955434,44670.7%
2025-09-16234,4513,639317,17273.9%
2025-09-15202,0052,548260,74577.5%
2025-09-12139,517307207,72167.2%
2025-09-11124,303300190,84265.1%
2025-09-10142,3120254,15656.0%
2025-09-09112,4950199,83556.3%
2025-09-08125,6940243,19151.7%
2025-09-05136,1374,123196,49069.3%
2025-09-04212,6560413,75151.4%
2025-09-03150,0860325,02546.2%
2025-09-02173,3110513,10333.8%
2025-08-2972,12727174,51041.3%
2025-08-2869,7785227,82630.6%
2025-08-27147,8660265,30455.7%
2025-08-26119,682471140,47385.2%
2025-08-2576,9670113,68267.7%
2025-08-22135,6042,740192,35470.5%
2025-08-21125,7300181,37769.3%
2025-08-20119,3910150,08979.5%
2025-08-19129,1530198,05865.2%
2025-08-18176,394200254,71469.3%
2025-08-15269,401700341,18479.0%
2025-08-14273,1561,009390,02170.0%
2025-08-13208,6800267,11678.1%
2025-08-12236,62194360,46165.6%
2025-08-11430,1460664,95364.7%
2025-08-08189,8150384,75049.3%
2025-08-07128,9810203,18163.5%
2025-08-0690,3893157,95757.2%
2025-08-0536,394064,18956.7%
2025-08-0476,2000104,24873.1%
2025-08-0189,2330115,45377.3%
2025-07-31105,933800152,57469.4%
2025-07-30129,4790204,16463.4%
2025-07-29155,2360232,32266.8%
2025-07-28161,6740233,44269.3%
2025-07-2578,05680164,29647.5%
2025-07-2471,971091,13779.0%
2025-07-2360,582090,35967.0%
2025-07-2272,1030157,34745.8%
2025-07-21144,8501,363258,32556.1%
2025-07-18170,16780221,77876.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.